Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Intensity Haploidentical HCT With Post-Transplant Cyclophosphamide in Advanced Myelofibrosis
NCT03118492Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Jun 2017
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cyclophosphamide, fludarabine and melphalan in myelofibrosis (MF), sponsored by City of Hope. Primary endpoints: Incidence of adverse events at 100 days and Incidence of unacceptable toxicity at 2 years. Started Jun 2017; status: active, not recruiting.
02
Drugs
cyclophosphamidefludarabinemelphalan
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT03118492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03118492.